Synnovation Therapeutics, a precision medicine company focused on the discovery and development of best-in-class targeted medicines, today announced the appointment of Rafael G. Amado, M.D., as a new ...

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...

Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat ...

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, ...

This highlights the urgent need for more effective treatment strategies. PARP1 is a widely targeted molecule in cancer treatment and, beyond its role in DNA repair, it participates in transcriptional ...

This study aimed to investigate how PCNA regulates DNA damage repair and cell cycle progression in HCC, with a focus on its interaction with poly (ADP-ribose) polymerase 1 (PARP1) and therapeutic ...

Dominantly inherited Alzheimer’s disease is caused by mutations in genes encoding molecules that control amyloid-β processing, which results in a predictable age of disease onset and a defined ...

When mutations hinder BRCA2 function, cancer cells are known to rely on the poly ADP-ribose polymerase 1 (PARP1) pathway for back-up DNA repair, and to continue abnormal growth. PARP inhibitors ...

A genetic predisposition may explain the enormous variability of this phenomenon, of which up to 47 symptoms have been identified. Contrary to popular belief, age has not been shown to worsen it ...

DNA damage response inhibitors are widely used anti-cancer agents that have potent activity against tumor cells with deficiencies in various DNA damage response proteins such as BRCA1/2. Inhibition of ...